BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
Want to see BIOA full AI Analyst Report?
Top Page
BioAge Labs, Inc.
(NASDAQ:BIOA)
Select Model
Select Model
Rating:50Neutral
Price Target:
$16.00
▼(-13.47% Downside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by heavy operating losses and substantial cash burn despite modest revenue, which dominate the financial profile. Technicals are neutral (no strong trend or momentum signal), and valuation is constrained by negative earnings. Offsetting these risks, the balance sheet is low-debt and corporate updates point to clinical progress and an extended cash runway.
Positive Factors
Conservative balance sheet
A very low debt-to-equity profile and substantial assets give BioAge financial flexibility to fund multi-year clinical programs without immediate leverage. This cushion reduces bankruptcy risk and supports strategic optionality through 2-6 months as trials progress.
Negative Factors
High cash burn
Sustained negative operating and free cash flow at this scale requires ongoing financing or major revenue growth. Over months this raises dilution risk, constrains discretionary spending choices, and makes execution reliant on preserving runway through financings or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A very low debt-to-equity profile and substantial assets give BioAge financial flexibility to fund multi-year clinical programs without immediate leverage. This cushion reduces bankruptcy risk and supports strategic optionality through 2-6 months as trials progress.
Read all positive factors
BioAge Labs, Inc. (BIOA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$738.36M
Dividend YieldN/A
Average Volume (3M)397.88K
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue Growth610.96%
EPS Growth-18.43%
CountryUS
Employees62
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.40
Shares Outstanding44,452,736
10 Day Avg. Volume402,040
30 Day Avg. Volume397,878
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)1.75
Price to Sales (P/S)52.85
P/FCF Ratio-5.77
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue37.57
Enterprise Value/Gross Profit37.81
Enterprise Value/Ebitda-4.20
Forecast
1Y Price Target
$47.83Price Target Upside158.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.55
Revenue Forecast (FY)$5.90M
BioAge Labs, Inc. Business Overview & Revenue Model
Company Description
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insi...
How the Company Makes Money
null...
BioAge Labs, Inc. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
74
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.32M | 8.99M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.25M | 8.99M | 0.00 | 0.00 | 0.00 |
| EBITDA | -92.37M | -79.69M | -68.58M | -55.90M | -39.35M |
| Net Income | -89.93M | -80.61M | -71.11M | -63.85M | -39.72M |
Balance Sheet | |||||
| Total Assets | 397.65M | 294.89M | 358.23M | 25.92M | 28.43M |
| Cash, Cash Equivalents and Short-Term Investments | 383.19M | 281.10M | 354.35M | 21.64M | 27.64M |
| Total Debt | 4.03M | 5.56M | 8.70M | 53.25M | 2.47M |
| Total Liabilities | 18.53M | 22.84M | 35.11M | 199.32M | 140.99M |
| Stockholders Equity | 379.12M | 272.05M | 323.13M | -173.40M | -112.56M |
Cash Flow | |||||
| Free Cash Flow | -88.63M | -82.35M | -51.89M | -37.53M | -36.28M |
| Operating Cash Flow | -88.31M | -81.63M | -51.52M | -37.36M | -36.18M |
| Investing Cash Flow | -63.98M | -95.22M | -366.00K | -266.00K | -103.00K |
| Financing Cash Flow | 136.68M | 11.47M | 381.20M | 34.94M | 2.50M |
BioAge Labs, Inc. Risk Analysis
BioAge Labs, Inc. disclosed 66 risk factors in its most recent earnings report. BioAge Labs, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioAge Labs, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $645.28M | 3.52 | -38.88% | ― | 13.80% | ― | |
53 Neutral | $164.11M | -14.36 | -35.57% | ― | 15.00% | 3.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $42.12M | -2.39 | -122.57% | ― | -100.00% | 54.21% | |
50 Neutral | $738.36M | -8.35 | -29.40% | ― | 610.96% | -18.43% | |
42 Neutral | $184.92M | -2.33 | -146.68% | ― | 0.47% | -430.88% |
* Healthcare Sector Average
BIOA
BioAge Labs, Inc.
16.61
12.66
320.51%
IRWD
Ironwood Pharma
3.92
3.35
592.58%
LFCR
Lifecore Biomedical
4.93
-1.79
-26.64%
SXTC
China SXT Pharmaceuticals
1.66
-230.84
-99.29%
DERM
Journey Medical Corp
5.96
-1.81
-23.29%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.52
-3.01
-46.10%
BioAge Labs, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
BioAge Highlights BGE-102 Progress and Financial Strength
Positive
Mar 24, 2026
BioAge Labs reported its full-year 2025 results and late-2025 operational milestones on March 24, 2026, highlighting strong progress for BGE-102, its oral, brain-penetrant NLRP3 inhibitor. Positive interim Phase 1 data in December 2025 and January...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.